Ipamorelin vs. CJC-1295
These two are the peanut butter and jelly of growth-hormone peptide marketing — so often sold together that comparing them individually already breaks the script. They act on different receptors: ipamorelin mimics ghrelin; CJC-1295 is a long-acting GHRH analog. Both prompt the pituitary to release growth hormone.
Both also share a regulatory rollercoaster: added to FDA's Category 2 compounding list in September 2023, removed in September 2024 after nomination withdrawals, and under continued review since. Whether a licensed pharmacy can compound either on a given day is a pharmacy question, not a settled fact.
The facts, side by side
| Ipamorelin | CJC-1295 (with DAC) | |
|---|---|---|
| Regulatory status | Compounded — eligibility varies | Research-stage — not approved for human use |
| Evidence level | Limited human data | Limited human data |
| Category | Muscle Growth | Muscle Growth |
Full profiles: Ipamorelin · CJC-1295 (with DAC)
Mechanism
Ipamorelin pulses the ghrelin receptor briefly and relatively selectively — early studies show little effect on cortisol or prolactin. CJC-1295 with DAC parks a GHRH signal in the body for about a week, raising GH and IGF-1 levels persistently. Pulse versus tide.
Human research depth
Ipamorelin reached early human trials (post-operative gut recovery) that were discontinued. CJC-1295's early studies measured hormone elevation; one research program was halted after a serious adverse event. Neither ever produced controlled trials on muscle, fat or aging outcomes.
The stack logic
The combination pitch — two receptors, synergistic release — is mechanistically plausible and clinically untested. No controlled human trial has measured what the stack does to body composition, which is the thing it's sold for.
The bottom line
A real comparison ends in a tie of absences: neither has human evidence for the outcomes they're marketed on, and both share the same moving regulatory ground. The honest questions are about the prescriber, pharmacy and monitoring — not which vial is 'better.'
Ipamorelin vs. CJC-1295 FAQ
More comparisons
Semaglutide vs. Tirzepatide
GLP-1 vs dual GIP/GLP-1 — how the two most prescribed weight-management peptides compare on evidence, average results, side effects and practical reality.
Tirzepatide vs. Retatrutide
One is an FDA-approved medicine; the other is an investigational triple agonist still in trials. The comparison that matters is regulatory status, not receptor count.
Semaglutide vs. Liraglutide
Two generations of the same drug class: how the weekly GLP-1 compares with its daily predecessor on results, track record and — increasingly — cost.
Build your own comparison